Periorbital Region

Oculoplastics

Congenital Ptosis May Stem From Fibrotic Changes to the Levator Aponeurosis

By

Rita Aghjayan

Publish Date September 10, 2021

The findings suggest a complex pathogenesis of simple congenital ptosis.

Oculoplastics

Quality of Life Tools Underused in Oculoplastics

By

K. Patricia Bouweraerts, MA

Publish Date March 11, 2021

An investigation shows a lack of research into postoperative quality of life for patients of certain oculoplastic procedures.

Periorbital Region

Study: Plasma Exeresis Is an Acceptable Alternative to Surgical Blepharoplasty

By

Jodi McCaffrey, MA, FACHE

Publish Date December 18, 2020

Researchers support the application of a noninvasive technique.

Periorbital Region

Upper Blepharoplasty May Raise Intraocular Pressure

By

Jodi McCaffrey, MA, FACHE

Publish Date September 15, 2020

Upper blepharoplasty may be associated with increased intraocular pressure.

Periorbital Region

ATV Accidents in Children Most Often Result in Head, Neck Injuries

Publish Date September 10, 2020

Head and neck injuries as a result of all-terrain vehicle (ATV) accidents remain common among children.

Periorbital Region

Violaceous Plaque On the Eyelid

By

Ronald Scott Bukoski, MS

Julia R. Nunley, MD

Publish Date September 8, 2020

When present, cutaneous sarcoidosis lesions are most often red-to-brown to violaceous papules and plaques.

Periorbital Region, Uncategorized

Teprotumumab Bests Placebo for Active Thyroid Eye Disease

Publish Date September 3, 2020

Outcomes better with teprotumumab vs placebo for proptosis, inflammation, diplopia, quality of life.

Periorbital Region, Systemic Ophthalmology

First Treatment for Thyroid Eye Disease Gets FDA Approval

By

Brian Park, PharmD

Publish Date September 2, 2020

The Food and Drug Administration (FDA) has approved Tepezza™ (teprotumumab-trbw; Horizon Therapeutics) for the treatment of thyroid eye disease.